Health and Pharmaceutical Litigation
Goodmans industry-leading legal work in the health and pharmaceuticals sector is unparalleled. We assist clients in the health and pharmaceutical industries with every aspect of their businesses, from regulatory advice and compliance to high-stakes litigation. Over the course of decades representing clients in these industries, we have developed deep industry knowledge and ties that generate efficient service for our clients.
When it comes to accessing the Canadian pharmaceutical market, no firm has more experience navigating the Patented Medicines (Notice of Compliance) Regulations (the PM(NOC) Regulations) than Goodmans. Since their inception in 1993, Goodmans has litigated dozens of patent proceedings pursuant to the PM(NOC) Regulations each year before the Federal Court. Our IP litigation bench is deep, with industry-recognized lawyers and leaders of the future working alongside several in-house PhD-level scientists. Goodmans is the “best patent litigation firm in Canada” (Chambers Canada) and “simply put, there is Goodmans and then there is the rest” (IAM Patent 1000).
Our lawyers have prosecuted numerous successful actions to recover monetary damages pursuant to section 8 of the PM(NOC) Regulations, with cumulative recovery for our clients in the hundreds of millions of dollars. Through this work, our lawyers have developed a vast network of contacts in forensic accounting and economics, who also assist our clients in defending against claims for monetary remedies for patent infringement. Our lawyers have been at the forefront of developing a principled, modern and sophisticated approach to assessing remedies for patent infringement in Canada.
When it comes to navigating the regulatory approval process for pharmaceuticals, Goodmans has more experience than any other firm addressing and successfully challenging the decisions of Health Canada, including by way of judicial review. After market approval, our lawyers have assisted pharmaceutical clients in high-stakes, “bet the company” challenges to regulatory decisions imperiling their ability to market their products in Canada. In addition, when regulatory decisions have caused our clients to suffer monetary damage, we have successfully acted in litigation to recover very significant remedies from the government.
Given our deep understanding of the Canadian and international pharmaceutical markets, we also advise pharmaceutical clients regarding pricing regulations and best practices before the Patented Medicines Prices Review Board (PMPRB), including hearings before the PMPRB. When trademark issues arise in the pharmaceutical industry, our lawyers have also consistently been called upon, resulting in precedential jurisprudence.
Our lawyers also regularly defend high-stakes product liability class actions in the pharmaceutical industry.
Awards & Recognition
Lexpert Special Edition: Technology and Health Sciences 2022 15 Goodmans lawyers recognized 2022
Lexpert Special Edition: Health Sciences 6 Goodmans lawyers recognized 2021
News & Events
Dispute ResolutionWe are delighted to announce the Lexpert Special Edition: Litigation 2022 once again features Goodmans partners among Canada's experts in litigation.Congratulations to our 13 featured partners:Andrew…
Health and Pharmaceutical Litigation
Harry Radomski at the World Law Group 2020 Spring eConference: International Regulatory Initiatives to Improve the Delivery of Healthcare in the Fight Against COVID-19Join Goodmans for the session "International Regulatory Initiatives to Improve the Delivery of Healthcare in the Fight Against COVID-19" at the World Law Group 2020 Spring eConference. …